Page last updated: 2024-12-06

lofentanil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lofentanil: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lofentanyl : The carboxamide resulting from the formal condensation of the aryl amino group of methyl 4-anilino-3-methyl-1-(2-phenylethyl)piperidine-4-carboxylate with propanoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123642
CHEMBL ID3990749
CHEBI ID61095
SCHEMBL ID1952939
MeSH IDM0107151

Synonyms (25)

Synonym
r 32792
lofentanyl
lofentanil
4-piperidinecarboxylic acid, 3-methyl-4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester
CHEBI:61095 ,
methyl 3-methyl-1-(2-phenylethyl)-4-[phenyl(propionyl)amino]piperidine-4-carboxylate
60645-00-3
lofentanila
lofentanilum
4-piperidinecarboxylic acid, 3-methyl-4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester, cis-(-)-
4-piperidinecarboxylic acid, 3-methyl-4-((1-oxopropyl)phenylamino)-1-(2-phenyleethyl)-, methyl ester, (3r,4s)-rel-(-)-
methyl cis-(-)-3-methyl-4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate
lofentanil [non stereospecific]
hsdb 8378
EPITOPE ID:153512
r-32792
SCHEMBL1952939
IMYHGORQCPYVBZ-UHFFFAOYSA-N
CHEMBL3990749
Q27130652
methyl 3-methyl-1-phenethyl-4-(n-phenylpropionamido)piperidine-4-carboxylate
methyl 3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate
methyl 3-methyl-1-(2-phenylethyl)-4-(phenyl(propionyl)amino)-4-piperidinecarboxylate
DTXSID10866851
AKOS040747114

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves were monotonic and the slopes were log-linear."( Epidural injections of bupivacaine, morphine, fentanyl, lofentanil, and DADL in chronically implanted rats: a pharmacologic and pathologic study.
Durant, PA; Yaksh, TL, 1986
)
0.27
" The slopes of the monotonic dose-response curves for the five opioids did not differ significantly."( Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat.
Durant, PA; Noueihed, RY; Yaksh, TL, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
piperidines
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (72.97)18.7374
1990's6 (16.22)18.2507
2000's3 (8.11)29.6817
2010's1 (2.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.38%)5.53%
Reviews2 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]